東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Biomedicine general." ]

切換: 標籤 | MARC模式 | ISBD

Immunotherapy of hepatocellular carc...

Greten, Tim F.

FindBook

Google Book

Amazon

博客來

Immunotherapy of hepatocellular carcinoma

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Immunotherapy of hepatocellular carcinoma/ edited by Tim F. Greten.
其他作者:	Greten, Tim F.
出版者:	Cham :Springer International Publishing : : 2017.,
面頁冊數:	x, 167 p. :ill., digital ;24 cm.
內容註:	Preface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.
Contained By:	Springer eBooks
標題:	Liver - Cancer -
電子資源:	http://dx.doi.org/10.1007/978-3-319-64958-0
ISBN:	9783319649580

Immunotherapy of hepatocellular carcinoma
Immunotherapy of hepatocellular carcinoma[electronic resource] /edited by Tim F. Greten. - Cham :Springer International Publishing :2017. - x, 167 p. :ill., digital ;24 cm.

Preface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.

In this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.

ISBN: 9783319649580

Standard No.: 10.1007/978-3-319-64958-0doiSubjects--Topical Terms:

3263980
Liver
--Cancer

LC Class. No.: RC280.L5

Dewey Class. No.: 616.9943606

Immunotherapy of hepatocellular carcinoma
LDR:02565nmm a2200313 a 4500 001 2110680
003 DE-He213
005 20180419142526.0
006 m d
007 cr nn 008maaau
008 180619s2017 gw s 0 eng d
020 $a 9783319649580 $q (electronic bk.)
020 $a 9783319649573 $q (paper)
024 7 $a 10.1007/978-3-319-64958-0 $2 doi
035 $a 978-3-319-64958-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L5
072 7 $a MBGR $2 bicssc
072 7 $a MED000000 $2 bisacsh
082 0 4 $a 616.9943606 $2 23
090 $a RC280.L5 $b I33 2017
245 0 0 $a Immunotherapy of hepatocellular carcinoma $h [electronic resource] / $c edited by Tim F. Greten.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a x, 167 p. : $b ill., digital ; $c 24 cm.
505 0 $a Preface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.
520 $a In this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
650 0 $a Liver $x Cancer $x Immunotherapy. $3 3263980
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Biomedicine general. $3 890966
700 1 $a Greten, Tim F. $3 3263979
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-64958-0
950 $a Biomedical and Life Sciences (Springer-11642)